Neosil
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Neosil Patents
Neosil has filed 1 patent.
The 3 most popular patent topics include:
- Arteries of the head and neck
- Honeycombs (geometry)
- Light machine guns
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/29/2020 | 1/4/2022 | Arteries of the head and neck, Roadsters, Light machine guns, Honeycombs (geometry), Lomanotidae | Grant |
Application Date | 4/29/2020 |
|---|---|
Grant Date | 1/4/2022 |
Title | |
Related Topics | Arteries of the head and neck, Roadsters, Light machine guns, Honeycombs (geometry), Lomanotidae |
Status | Grant |
Neosil Frequently Asked Questions (FAQ)
When was Neosil founded?
Neosil was founded in 2004.
Where is Neosil's headquarters?
Neosil's headquarters is located at 5980 Horton Street, Emeryville.
What is Neosil's latest funding round?
Neosil's latest funding round is Acquired.
How much did Neosil raise?
Neosil raised a total of $32M.
Who are the investors of Neosil?
Investors of Neosil include Peplin, MPM Capital, Shalon Ventures and Burrill & Company.
Who are Neosil's competitors?
Competitors of Neosil include Phico Therapeutics, Momenta Pharmaceuticals, Cerenis Therapeutics, Revance Therapeutics, Cara Therapeutics and 12 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Neosil to Competitors
Phico Therapeutics operates as a biotechnology company. It develops engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, particularly those caused by multi-drug resistant bacteria. The company was founded in 2000 and is based in Cambridgeshire, United Kingdom.
Sirion Holdings is a specialty pharmaceutical company focused on ophthamology drugs
Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases
Tequesta Marine Biosciences is a specialty pharmaceutical firm that develops small molecule therepeutic drugs for inflammatory conditions.
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
